MedX(R) Announces Agreement with Technology4Medicine To Expand Product Distribution in the U.S. Market



    Technology4Medicine to have exclusive U.S. distribution rights for MedX
    lasers in the dental, dermatology, plastic surgery and anti-aging
    markets; MedX will continue direct distribution for the U.S.
    Rehabilitation Market

    MISSISSAUGA, ON, July 15 /CNW/ - MedX Health Corp. (TSXV: MDX) today
announced an exclusive distribution agreement with Technology4Medicine, a
newly formed laser company based in San Clemente, CA, for the U.S. dental,
dermatology, plastic surgery and anti-aging markets. Technology4Medicine will
sell MedX Health's newest laser product, Oralase(TM) immediately upon
clearances from the Food and Drug Administration to dental offices. Oralase is
a low level laser therapy (LLLT) exclusively designed for dentists to
alleviate pain and accelerate tissue repair following dental procedures.
    "This partnership fulfills a key component of our vision for growth and
we are pleased to enter into this agreement with an exciting new company such
as Technology4Medicine," said Steve Guillen B.Sc., M.B.A., President & CEO,
MedX Health. "As we move forward with our business plan to become the
worldwide leader in light technology, MedX is committed to choosing the right
partners to accelerate product distribution while continuing to develop
superior products and explore new therapeutic opportunities for those
products. We believe that Technology4Medicine is the right partner to
penetrate the dental and other related markets in the United States through
their specialized, experienced sales staff."
    "MedX is already well established in the rehabilitation market, offering
innovative laser and light therapy products that have successfully treated
pain, sports injuries and other conditions," continued Guillen. "We believe
our products can offer patients with acute and chronic wounds a non-invasive,
drug free solution and we fully intend to pursue these indications
aggressively."
    The terms of the agreement include MedX giving Technology4Medicine
exclusive U.S. rights to sell Oralase and other MedX lasers that may be
applicable in the dental, dermatology, plastic surgery and anti-aging markets.
Increased levels of promotion are expected to cross over into these other
large growth markets.
    "This agreement helps put Technology4Medicine on the forefront of laser
product distribution," stated Jeff Jones, chief executive officer of
Technology4Medicine. "We chose MedX as our partner to bring the many benefits
of laser therapy to the US dental, aesthetic and other markets. This is a very
impressive technology that will further establish our company in the dental
industry with the best technology available. With Oralase, we believe we have
a winning formula for quick uptake and use in this $1 Billion marketplace. The
application of other MedX products in key U.S. markets such as aesthetic,
anti-aging and dermatology, makes this a very attractive partnership."

    About Oralase(TM)
    -----------------
    Oralase is an ergonomically designed portable low level laser device that
offers dental staff a proven, drug-free solution to eliminate pain and
accelerate soft and hard tissue repair. Oralase is designed to effectively
control pain and decrease swelling from invasive dental procedures as well as
stimulate healing. MedX has submitted to the FDA for marketing approval.
    MedX has developed products designed specifically for the dental market.
These products consist of the Oralase 200mw portable dental laser with
interchangeable intra-oral probes, an Oralase console system with three
accessories treating both intra and extra -orally, controlled by the compact
Model 1100 console, the MedX Home portable system for extra-oral treatment,
and the Oralase portable.
    The MedX dental product line offers dental staff a proven, drug free
solution to eliminate pain and accelerate soft and hard tissue repair. There
are over 325 dental research studies reporting positive effects of
photon/light therapy in more than 90% of the trials. Treatments are fast and
easy to set-up, 1-2 minute treatment times and excellent results for happier
patients
    MedX has developed and tested these products in dental clinics over the
last two years and believes that Oralase products will be in demand by
dentists as these products will provide the dentist with a competitive edge
and a high return on investment. MedX estimates that there are 150,000 dental
clinics in North America that can use these products resulting in a market
size of $1.1 Billion.

    About Low-Level Laser Therapy
    -----------------------------
    For more than 35 years, LLLT has been used in Europe, Australia, Asia and
Russia for the treatment of pain and tissue repair. LLLT was approved in
Canada in the early 1990's and in the United States in 2002. LLLT uses a
specific type of light to penetrate the skin's surface and underlying tissues
to stimulate the body's natural repair processes. The result is faster healing
and reduced pain, swelling and inflammation.

    About MedX Health Corp.
    -----------------------
    MedX is a leading North American developer and manufacturer of
phototherapy medical devices, including dental, rehabilitation and wound care
products. MedX is the world's only company focusing on developing and
delivering a broad cross-section of technologies and products involved in
healing using light therapy. MedX is committed to advocating for and bringing
the non-invasive, drug-free healing nature of light to people seeking relief
from pain and other physical ailments.
    MedX plans to use the proceeds from its recent public offering to expand
its distribution network; support its marketing program; continue development
of new dental, rehabilitation and wound care products; undertake research and
development for wound care products; and for working capital purposes. In
particular, MedX plans to accelerate the development of a new product aimed at
the rapidly-growing wound care market: its "Photobandage", a bandage
technology that allows a wound to be bathed in light, designed to enhance the
healing process. The Company intends to license this new technology to one or
more major wound care companies for further development, marketing and sales.

    About Technology4Medicine
    -------------------------
    Technology4Medicine (www.T4Med.com), and its Technology4Therapy division,
are committed to providing effective advanced technology to doctors and
patients improving clinical outcomes, enhancing the quality of care, enhancing
the patient experience and the clinician's return on investment.
Technology4Medicine is focused on ensuring customers have state-of-the-art
technology and the highest quality of customer support, technical service and
clinical training in the industry.
    Technology4Medicine was founded in early 2008 by the former
CEO/President, Jeffrey W. Jones, and Executive Vice President, Keith Bateman,
of Biolase Technologies, Inc (BLTI). Jones and Bateman grew Biolase from less
than $1 million in annual revenue to approximately $70 million and made
Biolase the world leader in laser dentistry. Jones and Bateman also founded
the World Clinical Laser Institute (WCLI) and grew it into the largest dental
laser education organization in the industry.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities
laws.

    %SEDAR: 00017466E




For further information:

For further information: Steve Guillen, President & CEO, MedX Health
Corporation, Phone: (905) 826-0766, Email: guillen@medxhealth.com; Jeff Jones,
Chief Executive Officer, Technology4Medicine, Phone: (949) 361-1682, Email:
jjones@t4med.com; Terri Clevenger, Continuum Health Communications, Phone
(203) 227-0209, Email: tclevenger@continuumhealthcom.com

Organization Profile

MedX Health Corp.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890